

Claim Amendments

Please amend the claims as shown below.

1. (previously presented) A crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ , wherein the crystalline solid famciclovir contains less than about 5% wt of another famciclovir crystalline form.
2. (previously presented) The crystalline solid famciclovir of claim 1, further characterized by a XRD pattern with peaks at 8.2, 10.4, 14.5, 17.0, 17.7, 19.5, 20.6, 21.1, 22.3, 23.0, 23.9, 24.4, 25.6, 26.5, 28.6, 29.0 and 32.6 ± 0.2 deg. 2θ .
3. (previously presented) The crystalline solid famciclovir of claim 2, wherein the XRD pattern is as substantially depicted in Fig. 1.
4. (canceled)
5. (previously presented) The crystalline solid famciclovir of any one of claims 1-3, wherein the crystalline solid famciclovir contains less than about 5% wt of form II.
6. (previously presented) The crystalline solid famciclovir of any one of claims 1-3, wherein the crystalline solid famciclovir contains less than about 1% wt of another famciclovir crystalline form.
7. (previously presented) The crystalline solid famciclovir of claim 5, wherein the crystalline solid famciclovir contains less than about 1% wt of form II.
8. (previously presented) A crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ , wherein the crystalline solid famciclovir contains less than about 5% wt of another famciclovir crystalline form.
9. (previously presented) The crystalline solid famciclovir of claim 8, further characterized by the XRD pattern having peaks at 8.3, 14.6, 17.8, 19.7, 20.7, 21.2, 24.5 and 25.6 ± 0.2 deg. 2θ .
10. (previously presented) The crystalline solid famciclovir of claim 9, wherein the XRD pattern is as substantially depicted in Fig. 2.
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)

15. (canceled)
16. (canceled)
17. (canceled)
18. (previously presented) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:
- a) triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether; and
 - b) isolating the crystalline solid famciclovir of claim 1.
19. (currently amended) A crystalline solid famciclovir ~~form I~~ characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ , wherein the crystalline solid famciclovir is prepared by triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether.
- 20-30. (canceled)
31. (previously presented) A process for preparing a mixture of crystalline solid famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ , and crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ , comprising the steps of:
- a) providing a solution of famciclovir in an organic solvent selected from the group consisting of chloroform, diethyl ether/dichloromethane mixture, tetrahydrofuran, acetonitrile/toluene mixture, dimethylacetamide and isopropanol,
 - b) cooling the solution, and
 - c) isolating the mixture of the crystalline solid famciclovir characterized by the XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ , and the crystalline solid famciclovir characterized by the XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ .
- 32-34. (canceled)
35. (previously presented) A process of preparing a crystalline solid famciclovir monohydrate, comprising the steps of:

- a) providing a solution of famciclovir in an ethanol/water mixture, DMF/water mixture, DMA/water mixture, acetonitrile/water mixture, methanol/water mixture, tetrahydrofuran/water mixture, and/or isopropyl alcohol/water mixture; and
 - b) cooling the solution; and
 - c) isolating the crystalline solid famciclovir monohydrate.
36. (canceled)
37. (previously presented) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 1 and a pharmaceutically-acceptable excipient.
38. (previously presented) The solid pharmaceutical composition of claim 37, wherein the crystalline solid famciclovir of claim 1 contains less than about 1% wt of another famciclovir crystalline form.
39. (previously presented) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 8 and a pharmaceutically-acceptable excipient.
40. (previously presented) The solid pharmaceutical composition of claim 39, wherein the crystalline solid famciclovir of claim 8 contains less than about 1% wt of another famciclovir crystalline form.
- 41-44. (canceled)
45. (previously presented) The crystalline solid famciclovir ethanol solvate of claim 15, containing less than about 5% wt of another famciclovir crystalline form.
46. (previously presented) The crystalline solid famciclovir ethanol solvate of claim 45, containing less than about 1% wt of another famciclovir crystalline form.
- 47-51. (canceled)